The tumor suppressor gene phosphatase and tensin homologue (PTEN) regulates the phosphatidylinositol-3 0 -kinase (PI3K) signaling pathway and has been shown to correlate with poor prognosis in high-grade astrocytomas when mutational inactivation or loss of the PTEN gene occurs. PTEN mutation leads to constitutive activation of protein kinase B (PKB)/Akt with phosphorylation at the PKB/Akt sites Thr-308 and Ser-473. Integrin-linked kinase (ILK) has been shown to regulate PKB/Akt activity with the loss of PTEN in prostate cancer. We now demonstrate that ILK activity regulates PKB/Akt activity in glioblastoma cells. The activity of ILK is constitutively elevated in a serum-independent manner in PTEN mutant cells, and transfection of wild-type PTEN under the control of an inducible promoter into mutant PTEN cells inhibits ILK activity. Transfection of ILK antisense (ILKAS) or exposure to a small-molecule ILK inhibitor suppresses the constitutive phosphorylation of PKB/Akt on Ser-473 in PTEN-mutant glioblastoma cell lines. In addition, the delivery of ILKAS to PTENnegative glioblastoma cells resulted in apoptosis. Rag-2M mice bearing established (B100 mg) human U87MG glioblastoma tumors, treated QD Â 5 for 3 consecutive weeks with ILKAS (i.p. 5 mg/kg), exhibited stable disease with p7% increase in tumor volume over the 3-week course of treatment. In contrast, animals treated with an oligonucleotide control or saline exhibited a >100% increase in tumor volume over the same time period. Our initial results indicate that therapeutic strategies targeting ILK may be beneficial in the treatment of glioblastomas.
Introduction
Glioblastoma multiforme (GBM) is the most common malignant brain tumor of adults, and has the distinction of being one of the most lethal, with a median survival of 9-12 months (Daumas-Duport et al., 1988) . The poor prognosis associated with GBM is due in large part to a lack of treatment options that consider the basic cancer biology that make GBM resistant to current therapies. In recent years, more attention has been given to signal transduction pathways that play key roles in the molecular pathogenesis of low-grade astrocytomas in their progression to GBM. PTEN/MMAC (phosphatase and tensin homologue on chromosome 10/mutated in multiple advanced cancers) is a tumor suppressor gene located on chromosome 10q23 (Li and Sun, 1997; Steck et al., 1997) that is mutated at a high frequency in glioblastomas and is known to regulate the phosphatidylinositol-3 0 -kinase (PI3K)/Akt pathway (Katso et al., 2001) . A homozygous disruption of PTEN results in embryonic lethality in mice, and germ-line mutations in PTEN are associated with the development of Cowden's disease and Bannayan-Zonana syndrome Marsh et al., 1997; Nelen et al., 1997; Tsou et al., 1997) . The frequency of PTEN mutation in glioblastomas, which has been shown to be as high as 80% , results in constitutive activation of protein kinase B (PKB)/Akt. PKB/Akt is a cell survival protein kinase that mediates its activity through various downstream effectors, resulting in cell migration, cell cycle progression, and an inhibition of apoptosis. In addition, PTEN mutation and increased PKB/Akt activity have been correlated with poor prognosis in glioma patients (Ermoian et al., 2002; Choe et al., 2003) .
Integrin-linked kinase (ILK) is a serine-threonine protein kinase containing four ankyrin-like repeats (Hannigan et al., 1996) which are found at the NH 2 terminus of ILK with a pleckstrin homology (PH)-like motif, and a catalytic kinase domain at its COOH terminal domain. ILK is a key component of cellextracellular matrix (ECM) adhesion and has been shown to anchor to integrins by interacting at its Cterminal domain to the cytoplasmic domain of b1 and b3 integrin subunits (Hannigan et al., 1996) . ILK also appears to interact with growth factor receptors via an adapter protein called PINCH (particularly interesting new cysteine-histidine-rich protein), which binds to Nck-2, an Src homology 2 (SH2) and SH3 domaincontaining adapter protein (Tu et al., 1998) . Since ILK can mediate signal transduction activity through its binding to b1 and b3 integrins, and the bridging of growth factor receptors via PINCH, ILK plays a key role in facilitating various cell signaling pathways. For example, ILK is involved in cell migration (Novak et al., 1998) , cell cycle progression (D'Amico et al., 2000) , growth and inhibition of apoptosis (Persad et al., 2000) -essentially the same cellular activities mediated by PKB/Akt. ILK therefore serves as an intermediate between PTEN regulation and PKB/Akt activation.
ILK has also been shown to have a potential oncogenic role giving rise to mammary tumors in transgenic mice , and it is expressed in neuroblastoma cells, ILK may also play a role in Alzheimer's disease by controlling tau phosphorylation (Ishii et al., 2003) . Knockdown of ILK protein by dominant-negative ILK and wild-type PTEN has resulted in the inhibition of PKB/Akt activity and apoptosis in prostate cancer cells (Persad et al., 2000) . Recently, ILK regulation by PTEN has been shown in glioblastomas in vitro (Obara et al., 2004) . Here we confirm that ILK and PKB/Akt are constitutively activated in human glioblastoma cells lacking PTEN expression. In addition, transfection of ILK antisense (ILKAS) or wild-type PTEN into these cells dramatically inhibits serum-independent PKB/Akt-Serine-473 (Ser-473) phosphorylation as well as PKB/Akt kinase activity, and leads to apoptosis or apoptosis sensitivity. Inhibition of ILK activity by a small-molecule ILK inhibitor also inhibits serum-independent PKB/Akt-Ser-473 phosphorylation. Treatment of U87MG xenograft tumors with an antisense oligonucleotide (ODN) that targets ILK results in tumor growth delay. These data demonstrate that ILK is critical for the PTEN-sensitive regulation of PKB/Akt-dependent cell cycle progression and cell survival, and is likely a valuable molecular target for the treatment of GBM.
Results

ILK activity and PKB/Akt-Ser-473 phosphorylation in PTEN-mutant human glioblastoma cells
There is now extensive evidence that mutational inactivation of the tumor suppressor PTEN occurs frequently in glioblastomas (Li and Sun, 1997; Steck et al., 1997; Wang et al., 1997; Knobbe et al., 2002) . PTEN mutation leads to elevated levels of the PI3-kinase product phosphatidylinositol-3,4,5 triphosphate (PI(3,4,5)P 3 ) and increased phosphorylation of PKB/ Akt on both Thr-308 and Ser-473 (Stambolic et al., 1998) . The purpose of these studies was to examine whether ILK regulates PKB/Akt in glioblastoma cells. Three glioblastoma cell lines were used: two PTEN negative, U251 and U87MG, and a PTEN-positive cell line, SF-188, as shown in Figure 1a . PKB/Akt-Ser-473 phosphorylation levels are high in glioblastoma cell lines (Haas-Koogan et al., 1998) , in association with PTEN inactivation. In order to determine if ILK, in accordance with its role as an upstream regulator of PKB/Akt activation, was also highly active with PTEN mutation, we examined ILK activity in these cell lines. This was measured by an ILK kinase assay, which used myelin basic protein (MBP) as a substrate. ILK activity was assessed in the PTEN-positive cell line SF-188 (Figure 1b ) and the PTEN-negative cell line U251 (Figure 1c ) cultured under serum-starved and serum refeeding conditions. Incorporated [ 32 P]ATP on MBP was detected by phosphoimaging and quantified by densitometry (Figure 1b and c). IgG controls for each cell line (first column) are provided for comparisons. ILK activity was elevated in the PTEN-positive SF-188 cells when cultured in serum-containing media (Figure 1b ). This increase in ILK activity was associated with PKB/ Akt phosphorylation (gel, Figure 1b) . ILK activity was low in the absence of serum and there was no measurable PKB/Akt phosphorylation as determined by Western blot analysis. Total ILK and PKB/Akt levels did not change regardless of whether cells were cultured in the absence or presence of serum (Figure 1b) . ILK activity is rapidly stimulated by serum and then starts to decrease after 40 min to basal levels, consistent with previous studies showing rapid ILK activation and decreasing activity to basal levels after 40 min while maintaining the cell survival activity of PKB/Akt (Delcommenne et al., 1998) (Figure 1b) . In contrast, ILK activity was high in the PTEN-negative U251 cells obtained from cultures in the presence or absence of serum (Figure 1c ). High ILK activity was associated with the presence of phosphorylated (Ser-473)Akt (Figure 1c) . Consistent with the SF-188 cells, total ILK and PKB/Akt were not affected by the culture conditions. These data demonstrate that, with the loss of PTEN, regulation of ILK and PKB/Akt activity is independent of the culture conditions (starved vs refeeding).
To determine the causal relationship between the regulatory loss of PTEN and the resulting ILK activity and subsequent PKB/Akt activity, PTEN-negative U87MG cells transfected with an ecdysone-inducible (Stolarov et al., 2001) wild-type-PTEN retroviral construct (designated here as U87.23) were obtained. The ecdysone-inducible expression system allows the expression of the PTEN gene in the presence of muristirone A. Consistent with previous reports, a concentration of 0.5 mM of muristirone A allows for the full expression of PTEN (Figure 2 ). The ILK and PKB/Akt activity of U87.23 with inducible PTEN was compared to that of the empty vector U87EVG retroviral construct in the presence and absence of muristirone A. When evaluating ILK activity (histogram), the vector control exhibited increased activity relative to the IgG control. Assessing the ILK activity in the PTEN-transfected cell line in the absence of muristirone showed an increase in ILK activity, albeit not as high as that observed in the vector control. This may be due to a low level of expression of PTEN, which was not detected using the immunoblot analysis methods described. The ILK activity was reduced significantly in U87.23 cells cultured with 0.5 mM muristirone. Decreasing ILK activity engendered by muristirone was associated with increased PTEN expression and decreased phospho-Akt expression (Figure 2 gels) . Total ILK and Akt protein levels did not change significantly regardless of whether PTEN was expressed or not. These data demonstrate the regulatory effects of PTEN on ILK activity and subsequently on PKB/Akt activity in glioblastoma cells.
The effect of ILK inhibition on glioblastoma cell survival
Since PKB/Akt is constitutively phosphorylated on Ser-473 in PTEN-mutant cells (Stambolic et al., 1998; Persad et al., 2000) , and having shown that ILK activity correspondingly decreases with phospho-Akt with or without PTEN induction (Figure 2 ), we wanted to determine if inhibiting ILK activity would result in inhibition of Akt phosphorylation. Two strategies were used to achieve ILK inhibition. A small-molecule inhibitor QLT0267 (QLT, Vancouver, BC, Canada) was used and previous generations of this inhibitor have shown therapeutic activity in a variety of tumor models (Tan et al., 2002 (Tan et al., , 2004 Edwards et al., 2004) ; alternatively, an antisense molecule was used that we have shown to downregulate ILK expression effectively in glioblastoma cells (Edwards et al., 2003) . As shown in Figure 3a , increasing concentrations of the ILK inhibitor QLT0267 (i.e. 0-100 mM) resulted in decreased Akt phosphorylation on Ser-473 in U87MG glioblastoma cells. We also assessed the impact of U87MG cells treated with an ILK-targeted antisense ODN (ILKAS). The first studies evaluated the impact of the ILKAS on ILK expression in comparison to various controls including untreated cells (Figure 3b ; CNT), liposomal vector alone ( Figure 3b ; VEC), and a reverse ILKAS sequence (Figure 3b ; RILK). These data demonstrate that treatment with the ILKAS (Figure 3b ) inhibits ILK protein expression, as judged by ILK protein levels determined 24 h post-transfection. A time-course study suggested that ILKAS-mediated suppression of ILK was greater at 24 h than at 12 h and that ILK downregulation was associated with decreased (B60%) phospho-Akt at Ser-473 activity ( Figure 3c ). Importantly, transfection of the U87MG cells (PTEN negative) with the ILK-targeted antisense did not affect phospho-Akt at Thr-308, consistent with the conclusion that ILK specifically phosphorylates PKB/Akt at Ser-473.
Inhibition of ILK induces apoptosis in PTEN-negative glioblastoma cells
It has previously been shown that ILK activity can be suppressed by nonsteroidal anti-inflammatory drugs (NSAIDs), such as a COX-2 inhibitor, which can result in decreased glioblastoma cell viability (Obara et al., 2004) . Given that ILK inhibition leads to decreased activity of the cell survival kinase Akt, we wanted to see if this would induce apoptosis. To determine what the effects of antisense-mediated ILK inhibition were on the glioblastoma cells, we also examined U87MG cells by PI and 4 0 ,6-diamidino-2-phenylindole (DAPI) staining (Figure 4b and c) . PI was used to stain the nuclear DNA content of control and ILKAS-treated U87MG cells. Cells undergoing apoptosis and necrosis were identified as a population with decreased DNA content (the sub-G 1 /G 0 population). The sub-G 1 /G 0 U87MG treated with ILKAS (Figure 4b , far right panel) was compared to U87MG cells treated with a reverse antisense (Figure 4b , middle panel) and U87MG untreated control cells (Figure 4b , far left panel). The ILKAS showed a 70% sub-G 1 /G 0 cell fraction of DNA by PI staining which is indicative of apoptosis, compared to a 15.7% sub-G 1 /G 0 population observed in untreated U87MG control cells. The sub-G 1 /G 0 cell fraction observed following treatment with the reverse antisense was higher than the untreated cell fraction (31.1 vs 15.7%). This is likely due to toxicity associated with the transfection method used. Regardless, the sub-G 1 /G 0 cell fraction observed when cells were treated with the reverse antisense was still significantly lower than that observed following treatment with the ILKAS.
To confirm whether transfection of glioblastoma cells with ILKAS resulted in apoptotic cell death, we assessed the morphological changes of DAPI-stained U87MG cells (Figure 4c ). Nuclear fragmentation and chromatin condensation were seen in U87MG cells treated with the reverse antisense (Figure 4c 
Antitumor efficacy of ILKAS on PTEN-negative glioblastoma U87MG tumor xenografts
Although the small-molecule ILK inhibitor is of interest, and in vivo studies assessing the activity of the small-molecule inhibitor QLT0267 in murine models of glioblastoma are ongoing, we report here on the in vivo efficacy studies on ILKAS. Prior to initiating in vivo studies on PTEN-negative glioblastoma tumors, we examined by immunohistochemistry the expression of PTEN and phospho-(Ser-473)Akt in tumors generated following subcutaneous injection of the three glioblastoma cell lines in this study ( Figure 5 ). Tumors grown in Rag-2M mice were derived from the PTEN-negative glioblastoma cell lines U87MG and U251 and the PTEN-positive cell line SF-188. Similar to the Western blot analysis (Figure 1a) , PTEN staining (orange-red stain) was clearly seen in the PTEN-positive SF-188 tumor section (Figure 5a ), but not in the PTEN-negative U87MG (Figure 5b ) or U251 tumor sections (Figure 5c ). In addition, phospho-Akt staining specific for Ser-473 was observed in the PTEN-negative tumors U87MG (Figure 5e ) and U251 (Figure 5f ), but very little was observed in the PTEN-positive SF-188 tumor section (Figure 5d ). This suggests that PTEN and PKB/Akt expression levels are consistent when comparing the in vitro and the in vivo results. Figure 5g and h are representative negative IgG controls.
We tested the antitumor effects of the ILKAS in Rag-2M mice bearing established (B100 mg) subcutaneous (s.c.) xenografts of U87MG (PTEN negative) glioblastoma tumors. Saline-treated control tumors grew reproducibly to an average size of 0.32 cm 3 within 21 days following initiation of the study (Figure 6a ). Treatment (qdx5 every week for 3 weeks) with a scrambled antisense (SCRAM 2) did not cause any Figure 5 Immunohistochemistry of SF-188, U87MG, and U251 tumors generated in Rag-2M mice stained for PTEN (orange-red stain) and phosphorylation of PKB/Akt-Ser-473 (orange-red stain) expression. PTEN expression was seen in the PTEN-positive cell line SF-188 (a), and not seen in U87MG (b) or U251 (c) glioblastoma cells. PKB/Akt phosphorylation at Ser-473 cannot be seen in the PTEN-positive SF-188 glioblastoma cell line (d), but is seen in the PTEN-negative glioblastoma cell lines U87MG (e) and U251 (f). IgG controls for PTEN (g) and phospho-PKB/Akt (h) IgG controls are shown above significant change in tumor growth rate when compared to the saline control. When comparing the control animals to the ILKAS-treated animals, the tumor size in the ILKAS-treated group was significantly lower (Po0.05) at all measured time points. None of the mice treated with the ILKAS displayed signs of toxicity, and the ILKAS dose used was consistent with previous studies from our laboratory using antisense therapeutics (Hu et al., 2003; Waterhouse et al., 2004) .
To confirm the activity of ILKAS in vivo, Western blots were carried out on harvested tumors from control and treated mice where tumors were harvested at the end of the 3-week treatment period (Figure 6b ). ILK protein levels were decreased in ILKAS-treated mice (5 mg/kg) in contrast to untreated control tumors which showed no decrease in ILK protein levels. Mice treated with scrambled ODNs (5 mg/kg) exhibited no loss of ILK protein. To further evaluate ILKAS-mediated therapeutic activity, ILK protein suppression and Akt phosphorylation were assessed using immunohistochemistry. Sections derived from isolated U87MG tumors were stained for ILK and phospho-Akt at Ser-473 (Figure 7 ). U87MG control tumors (saline treated) showed staining for ILK and PKB/Akt phosphorylated at Ser-473 (Figure 7b and e, respectively). U87MG tumors obtained from ILKAS-treated animals revealed a significant loss of ILK and phospho-(Ser-473)Akt staining (Figure 7c and f, respectively) . Figure 7a and d are representative IgG controls. These results indicate that the ILKAS used in these studies can mediate decreased tumor growth rates, decreased ILK expression, and decreased phospho-(Ser-473)Akt.
Discussion
PTEN mutation in glioblastomas has been shown to influence the PI3-kinase pathway (Choe et al., 2003) and more specifically PKB/Akt levels and activity (Knobbe et al., 2002) , VEGF levels (Pore et al., 2003) , cellular invasion (Park et al., 2002) , and cell cycle regulation (Cheney et al., 1999) . Similarly, integrin-linked kinase has been shown to regulate PKB/Akt (Persad et al., 2001 ) in a PI3-kinase-dependent manner (Delcommenne et al., 1998) . This ILK-regulated pathway affects cellular invasion and cell cycle regulation (D'Amico et al., 2000) . Despite the parallel in cellular regulation between PTEN and ILK and the subsequent downstream PKB/Akt activity in glioblastomas, the role of ILK in glioblastoma cells has not been well described. The present study sought to characterize the role of integrin-linked kinase in glioblastoma cells in vitro and the potential for modulating constitutive ILK protein expression and activity by treatment with an ILK-targeted antisense sequence. Preliminary results with a small-molecule inhibitor of ILK are also provided.
The in vivo data suggest that ILK suppression, induced by treatment with antisense-targeting ILK, causes a tumor growth delay. It is possible that this approach will be sufficient to stabilize diseases but will not be able to promote tumor regression based on these results with well-established tumors (Figure 6a ). Consistent with other studies from this laboratory (Edwards et al., 2003 (Edwards et al., , 2004 , it is anticipated that molecularly targeted drugs need to be combined with other agents in order to obtain optimal therapeutic results such as tumor regression. The use of ILKAS for treatment of the brain cancer GBM may, for example, be most effective in combination with conventional drugs used in treating this disease (e.g. Temozolimide) or with other drugs targeting parallel pathways capable of compensating for ILK inhibition. Our approach involves targeting cell-signaling pathways known to be involved in the progression of brain cancer and targeting via smallmolecule inhibitors or antisense in drug combinations that would ideally be synergistic. To this end, previous studies have shown that PD153035, an inhibitor of the highly expressed EGFR in glioblastomas, in combination with a small-molecule inhibitor-targeting ILK, Figure 6 (a) Representative study of tumor growth delay by ILKAS in Rag-2M mice bearing established U87MG xenograft tumors. ILKAS or a SCRAM control sequence was injected i.p. into Rag-2M mice and the resulting tumor growth curves were compared to saline-treated control animals over a 3-week period. Bars: pretreatment (horizontal hatched bars), week 1 (gray bars), week 2 (black bars), week 3 (white bars). The tumor inoculation and treatment schedules are described in 'Materials and methods.' All data are expressed as mean7s.e. (n ¼ 6 mice/group) Pp0.05 for treatment groups compared with controls (saline) and these are indicated with an *. (b) Western blotting analysis of ILK and actin protein levels of harvested tumors from untreated, SCRAM2-, and ILKAS-treated Rag-2M mice were quantitated by densitometry. ILK and actin protein levels are normalized to untreated control tumors and values are shown below yielded a synergistic interaction and resulted in increased cell death (Edwards et al., 2004) . However, in our previous study and in the current study, it is important to note that in dealing with molecularly targeted drugs alone or in combination, it is critical to assess many therapeutic end points, particularly in defining drug efficacy and drug interactions which appear to be synergistic.
Our lab is currently pursuing how to translate drug efficacy and drug interactions measured on the basis of cell-based screening assays to preclinical studies of drug combinations and, eventually, to clinical trials. The later point is obviously critical, since use of the antisense against ILK may only result in patients with stable disease and this effect may not be sufficient to warrant further clinical development as a single agent. Yet, the same drug may show substantial therapeutic effects in a combination setting.
Regardless of how ILK inhibition is achieved, it is clear that it is an important therapeutic target and strategies assessing ILK inhibitors require serious consideration.
ILK has been shown to be important in oncogenesis and is a principal mediator of cell-signaling activity within the PI3-kinase cell signaling pathway. Integrinlinked kinase has been associated with cell proliferation in ovarian cancer cells (Cruet-Hennequart et al., 2003) , ILK expression has also been shown to increase with prostate tumor grade (Graff et al., 2001) , and is a potential diagnostic marker for Ewing's sarcoma and primitive ectodermal tumors (Chung et al., 1998) . It is clear that ILK plays a major role in cancer progression and glioblastomas are part of ILK's oncogenic repertoire.
Materials and methods
Cell culture, transfections, and antisense
Three human glioblastoma cancer cell lines were used in this study: SF-188, U87MG, and U251. Cells were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum with 1% L-glutathionine and 1% penicillin/ streptomycin at 371C in a humidified atmosphere containing 5% CO 2 . For all experiments, cells were used in exponential growth phase. U87MG cells were transiently transfected with ILKAS using Lipofectamine 2000t reagent (Invitrogen, MD, USA) according to the manufacturer's guidelines using 1-4 mg (optimally 2 mg) antisense, and 12 ml Lipofectamine 2000t reagent in 10 cm 3 tissue culture dishes. Retroviral constructs with either PTEN empty vector (U87EVG) or with an inducible PTEN construct (U87.23) were generously provided by Dr Michael Wigler (Cold Spring Harbour). U87 cells with the various vector constructs were maintained with hygromycin selection at 50 mg/ml. Muristirone A (Invitrogen) was reconstituted in 100% ethanol prior to adding to cells for induction. Cells were harvested 24-48 h later. An ILKAS sequence was selected from a patent filed by ISIS Pharmaceuticals Inc. (Carlsbad, CA, USA). Sequence ID no. 37 (5 0 -GAGATTCTGGCCCATCTTCT-3 0 ) was used and is designated here as ILKAS. ILKAS is a 20mer antisense ODN with a phosphothioate backbone, 5 0 -methylcytidines with the first five nucleotides (at the 5 0 -end) 2 0 O-methyls and the last five nucleotides (at the 3 0 -end) 2 0 O-methyls. The ILKAS affects the 635 'coding region' or open reading frame (ORF), which lies between the translation initiation codon and the translation termination codon of human ILK. A nonsilencing antisense sequence was also obtained, designated SCRAM2, and a reverse polarity antisense (RILK) was also used with the same modifications as those of ILKAS. Antisense sequences for in vitro use were generated at the University of British Columbia Nucleic Acid Protein Service Unit (Vancouver, BC, Canada). Antisense sequences were ammonia-butanol purified. Antisense sequences for in vivo use were generated at Eurogentec (Philadelphia, PA, USA).
ILK kinase assays
ILK kinase activity was determined in cell extracts by immunoprecipitation in vitro kinase assays, as detailed elsewhere (Hannigan et al., 1996; Delcommenne et al., 1998) . In brief, MBP was used as a substrate for ILK, [ 
Western blot
The following antibodies were used in this study: anti-ILK (affinity-purified rabbit polyclonal, Upstate Biotechnology, Virginia, USA); anti-P-Akt-Ser-473, anti-P-Akt-Thr-308, anti-ILK, anti-Akt (New England Biolabs, Canada) and antihuman b-actin (Sigma, St Louis, MO, USA), and anti-HA (Roche, Mannheim, Germany). The secondary antibody used was horseradish-conjugated anti-mouse or anti-rabbit IgG (Promega, Madison, WI, USA). Densitometric analysis was done and then normalized to control or time 0 samples. For in vivo ODN-treated and untreated tumors, the tumor tissue was lysed (using a mortar and pestle) with ice-cold lysis buffer (50 mM Tris, 150 mM NaCl, 2.5 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, and 0.02% sodium azide) containing protease inhibitors (Complete-Mini protease inhibitor tablets: Boehringer Mannheim GmBH, Mannheim, Germany). After incubation for 30 min on ice, samples were centrifuged at 10 000 r.p.m. for 15 min, and stored at À201C. Protein content in the lysed extracts was determined using a detergent-compatible Bio-Rad assay (Bio-Rad Labs, Hercules, CA, USA). Similarly, for in vitro ODN-treated cells and untreated cells, cells were lysed with ice-cold lysis buffer containing protease inhibitors. After incubation for 15 min on ice, samples were centrifuged at 5000 r.p.m. for 10 min. Proteins were detected by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech, Buckinghamshire, England) and visualized after exposure to Kodak autoradiography film. Equivalent amounts of protein (30 mg determined by Bradford assay) were resolved by 12% SDS-polyacrylamide gels or 4-15% gradient SDS-polyacrylamide pre-made gels (BioRad).
Nuclear morphology
Untreated and treated cells were incubated a minimum of 12 h in medium at 371C without additional drug treatment. Cells were then harvested and stained with 0.10 mg/ml DAPI for 30 min at room temperature. Cells were cytospun onto a glass slide, and viewed with a Leica microscope (Germany) with a Â 40 objective lens under UV fluorescent illumination. Images were captured using DC100 digital camera and Imagedatabase V. 4.01 Software (Leica, Germany).
Flow cytometric assay of apoptosis 5 Â 10 5 cells were cultured with or without antisense and later incubated for a minimum of 12 h in culture media at 371C without additional drug treatment. Cells were treated with ILKAS. Control cells were untreated or treated with reverse ILKAS sequence (RILK). Note, a liposomal vector control was also included in the experiment, which had no effect (data not shown). Cells were then harvested and fixed with cold 70% ethanol stored overnight at À201C and stained with PI staining buffer (1 mg/ml RNase A, 0.1% Triton X-100, 50 mg/ml PI in PBS) to determine the apoptotic/necrotic cell population (the sub-G 1 /G 0 cell fraction). In order to evaluate the early stages of apoptosis, treated cells were stained with Annexin V-FITC (CALTAG) in Annexin V staining buffer for 15 min at room temperature and counterstained with 50 mg/ml PI in Hank's balanced salt solution (Stem Cell Technologies) with no phenol red and analysed with a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA).
Animal xenograft models and antitumor activity
Male Rag-2M mice (7-9 weeks old, 20-27 g) were obtained from the British Columbia Cancer Agency Joint Animal Facility breeding colony, and housed in an aseptic environment. A solid tumor model of SF-188, U87MG, and U251 cells in Rag-2M mice was established by subcutaneous inoculation of 5 Â 10 6 cells on the back of mice. All of the animal protocols were approved by the University of British Columbia Animal Care Committee and the studies were conducted in accordance with the guidelines of the Canadian Council of Animal Care.
Efficacy experiments were conducted in male Rag-2M mice bearing U87MG tumors (six mice per group). Treatments were initiated on day 22-post cell inoculation. Saline control, ILKAS or scrambled control (SCRAM2) ODNs were administered using a treatment schedule of i.p. injections given once a day (QD) for 5 days, followed by 2 days off, for a 3-week period at a dose of 5 mg/kg. Mice were observed daily and body weight measurements and signs of stress (e.g. lethargy, ruffled coat or ataxia) were monitored. Having previously determined the maximum tolerated dose exceeded 20 mg/kg in Rag-2M mice, none of the mice treated with ILKAS showed any indication of toxicities at the 5 mg/kg dose of the ILKAS. Electronic calipers (Mitutoyo corp., Japan) were used to measure tumors and the mean tumor size (mm 3 ) was determined using the formula 1 2 (length (mm)) Â (width (mm)) 2 . The tumor size per mouse was used to calculate the group mean tumor size7s.e. (n ¼ 6 mice). The results are a representative graph of at least three experiments.
Histopathology of tumors
Mouse tumors were collected 1 day after the final treatment, one portion of the tumor tissue was fixed in formalin. Paraffinembedded tissues were sectioned and were subjected to gross histopathology using hematoxylin & eosin (H&E) staining. The other portion of the tumor tissue was placed in phosphate-buffered saline (PBS) and immunohistochemistry for floating sections was performed using anti-ILK, antiphospho-PKB/Akt Ser-473, anti-PTEN, and anti-IgG (New England Biolabs, Canada) antibodies according to the manufacturer's instructions. All tissue sections and subsequent staining was carried out by Criterion Laboratories (Vancouver, BC, Canada).
Statistical analysis
All of the statistical analyses were performed using the STATISTICA software program. Data analysis for multiple comparisons of treatment and control groups was carried out using the one-way ANOVA Tukey test. Data were considered significant for P-value o0.05. The in vivo experiments were performed three times (n ¼ 6 mice/group). The data shown in this paper represent the final experiment of three.
Abbreviations ILK, integrin-linked kinase; PI3K, phosphatidylinositol-3 0 -kinase; PTEN, phosphatase and tensin homologue; MMAC1, mutated in multiple advanced cancers; PI(3, 4, 5) P3, phosphatidylinositol-3, 4, 5-triphosphate; DAPI, 4 0 ,6-diamidino-2-phenylindole; CI, combination index; GBM, glioblastoma multiforme; ODN, oligonucleotides.
